Back to results
US 2026/0007783 A1Published application
A 3E8.scFv.Cys-IR800 Conjugate Targeting TAG-72 in an Orthotopic colorectal cancer model
AssigneeOhio State Innovation Foundation
InventorsMichael F. Tweedle, Li Gong
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions are anti-TAG-72 imaging agents and methods of their usc.
Claims11
1-18. (canceled)
A method of monitoring recurrence of a cancer in a subject following surgical removal of said tumor the method comprising:
- a. administering to a subject intraperitoneally an anti-tumor-associated glycoprotein 72 (TAG-72) imaging agent comprising the formula Y-R, wherein Y comprises an anti-TAG-72 binding moiety and R comprises a first detectable label;
- wherein the first detectable label “R” comprises any dicyanine dye that emits fluorescent light that is detectable on a clinical optical near infrared fluorescence-(NIRF) imager above 800 nm;
- wherein the dicyanin dye is selected from the group consisting of infrared (IR) dye800, AlexaFluor 790, ZW-800, Indocyanine Green, and S0456;
- wherein the anti-TAG-72 binding moiety comprises 3E8.scFv;
- and
- b. monitoring for the presence of the detectable label of bound anti-TAG-72 binding moiety;
- wherein the presence of bound anti-TAG-72 binding moiety indicates a recurrent cancer.
4 more elements
A method of monitoring the progression of a cancer in a subject the method comprising:
- a. administering to a subject intraperitoneally an anti-tumor-associated glycoprotein 72 (TAG-72) imaging agent comprising the formula Y-R, wherein Y comprises an anti-TAG-72 binding moiety and R comprises a first detectable label;
- wherein the first detectable label “R” comprises any dicyanine dye that emits fluorescent light that is detectable on a clinical optical near infrared fluorescence-(NIRF) imager above 800 nm;
- wherein the dicyanin dye is selected from the group consisting of infrared (IR) dye800, AlexaFluor 790, ZW-800, Indocyanine Green, and S0456;
- wherein the anti-TAG-72 binding moiety comprises 3E8.scFv;
- and
- b. monitoring for a change in the level of the detectable label of bound anti-TAG-72 binding moiety;
- wherein an increase in the level of detectable bound anti-TAG-72 binding moiety indicates a the cancer is increasing, no change in the level of detectable bound anti-TAG-72 binding moiety indicates the cancer is not progressing;
- and a decrease in the level of detectable bound anti-TAG-72 binding moiety indicates the cancer is shrinking.
5 more elements
Dependencies are inferred from the claim text.